Review of Pharmacology - 9E (2015)

Review of Pharmacology
218. Ans. (b) Phenoxybenzamine (Ref: KDT 6/e p133)
219. Ans. (c) Hydrolysis by blood esterase (Ref: KDT 6/e p141)
220. Ans. (d) All of above (Ref: KDT 6/e p139)
221. Ans. (d) Phenoxybenzamine binding to alpha adrenergic receptors (Ref: Katzung 10/e p16; KDT 6/e p133)
• Phenoxybenzamine is an irreversible (covalent) antagonist at alpha receptors. All other drugs mentioned are
reversibly interacting with their receptors.
Answers of recent Questions asked by National Board
Autonomic Nervous System
1. Ans (a) Atenolol (Ref. KDT 7th/40)
2. Ans (a) Causes increase in GI Ischemia (Ref. KDT 7th/134)
Dopamine causes vasodilation in renal and splanchnic vessels by stimulating D 1
receptors.
3. Ans. (a) Acute CHF (Ref: KDT 6/e p142)
4. Ans. (a) Adrenaline (Ref: KDT 6/e p122)
5. Ans. (c) Neostigmine (Ref: KDT 6/e p104)
6. Ans. (a) Adrenaline (Ref: KDT 6/e p130)
7. Ans. (b) Carbaryl (Ref: KDT 6/e p105)
8. Ans. (c) Pindolol (Ref: KDT 6/e p140)
9. Ans. (d) Absence of pulmonary secretions (Ref: emedicine.medscape.com)
10. Ans. (a) Atropine (Ref: KDT 7/e p118)
11. Ans. (b) Alpha 2 (Ref: KDT 7/e p565)
12. Ans. (b) Adjuvant pharmacotherapy for BMI > 30 kg/m 2 (Ref: CMDT 2014/1215)
NIH Clinical obesity guidelines recommend
• Lifestyle modification for all
• Surgery for patients with:
––
BMI >40 kg/m 2
––
BMI >35 kg/m 2 with obesity related co-morbidities
• Pharmacotherapy for patients with:
––
BMI >30 kg/m 2
––
BMI >27 kg/m 2 with obesity-related risk factors.
13. Ans. (b) Fludrocortisone (Ref: CMDT 2014/941)
14. Ans. (a) Atropine (Ref: KDT 7/e p146)
• Dopamine, adrenaline and isoprenaline act by stimulating b 1
receptors in heart. As patient has b-blocker overdose,
these are likely to be ineffective
• Atropine can increase heart rate in this person by blocking parasympathetic action on heart.
15. Ans. (c) Yohimbine (Ref: KDT 7/e p140)
16. Ans. (a) Mucous and pharyngeal secretions (Ref: KDT 7/e p113-115)
17. Ans. (c) Bradycardia (Ref: KDT 7/e p114)
18. Ans. (d) Intramuscular (Ref: KDT 7/e p138)
19. Ans. (a) Tamsulosin (Ref: KDT 7/e p142)
20. Ans. (a) Tamsulosin (Ref: KDT 7/e p142)
21. Ans. (b) Shorter acting than edrophonium (Ref: KDT 7/e p105-109)
22. Ans. (a) Glaucoma (Ref: KDT 7/e p121)
108
https://kat.cr/user/Blink99/